Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
- 18 January 2018
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 378 (3), 250-261
- https://doi.org/10.1056/nejmoa1709449
Abstract
Sporadic arteriovenous malformations of the brain, which are morphologically abnormal connections between arteries and veins in the brain vasculature, are a leading cause of hemorrhagic stroke in young adults and children. The genetic cause of this rare focal disorder is unknown. We analyzed tissue and blood samples from patients with arteriovenous malformations of the brain to detect somatic mutations. We performed exome DNA sequencing of tissue samples of arteriovenous malformations of the brain from 26 patients in the main study group and of paired blood samples from 17 of those patients. To confirm our findings, we performed droplet digital polymerase-chain-reaction (PCR) analysis of tissue samples from 39 patients in the main study group (21 with matching blood samples) and from 33 patients in an independent validation group. We interrogated the downstream signaling pathways, changes in gene expression, and cellular phenotype that were induced by activating KRAS mutations, which we had discovered in tissue samples. We detected somatic activating KRAS mutations in tissue samples from 45 of the 72 patients and in none of the 21 paired blood samples. In endothelial cell–enriched cultures derived from arteriovenous malformations of the brain, we detected KRAS mutations and observed that expression of mutant KRAS (KRASG12V) in endothelial cells in vitro induced increased ERK (extracellular signal-regulated kinase) activity, increased expression of genes related to angiogenesis and Notch signaling, and enhanced migratory behavior. These processes were reversed by inhibition of MAPK (mitogen-activated protein kinase)–ERK signaling. We identified activating KRAS mutations in the majority of tissue samples of arteriovenous malformations of the brain that we analyzed. We propose that these malformations develop as a result of KRAS-induced activation of the MAPK–ERK signaling pathway in brain endothelial cells. (Funded by the Swiss Cancer League and others.)Keywords
Funding Information
- Alcon Research Institute (14B065)
- Swiss Cancer League (LSCC 2939-02-2012)
- Canada Foundation for Innovation equipment grant
- European Research Council
- Canadian Institutes of Health Research (MOP-119506)
- Medicine by Design
- American Heart Association Grant in Aid (16GRNT31330023)
This publication has 38 references indexed in Scilit:
- Somatic Activating PIK3CA Mutations Cause Venous MalformationAmerican Journal of Human Genetics, 2015
- A Somatic MAP3K3 Mutation Is Associated with Verrucous Venous MalformationAmerican Journal of Human Genetics, 2015
- Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibitionOncogene, 2012
- Mechanisms and functions of p38 MAPK signallingBiochemical Journal, 2010
- Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformationsNature Genetics, 2008
- Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused byRASA1 mutationsHuman Mutation, 2008
- A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 ( SMAD4)The Lancet, 2004
- Incidence and prevalence of intracranial vascular malformations in Olmsted County, Minnesota, 1965 to 1992Neurology, 1996
- Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1Nature Genetics, 1994
- ARTERIOVENOUS MALFORMATION OF THE BRAIN.1965